FISHER & PAYKEL HEALTHCARE C

Fisher & Paykel Healthcare declares a 30% dividend, revealing strong cash flow and growth while backing next‑gen medical devices and patient‑centric care.

Fisher & Paykel Healthcare’s Q4 2025 update shows robust cash, 12% cash‑flow growth, and a 55% margin—fueling R&D, value‑based pricing, and strategic expansion in global healthcare markets.

Fisher & Paykel Healthcare’s latest earnings show steady growth driven by high‑margin respiratory and anaesthesia products, robust pipeline, and tariff‑mitigation strategies.

FPHC director Graham McLean boosts stake to 4,900 shares, underscoring confidence amid rising NAV and active buyback plans—key insights for investors.